Clinical Trial Update: Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial update shows mild-dose IMRT after GELOX chemotherapy achieving complete tumor response in early-staged extranodal nasal-type NK/T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma Nasal Type
• Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• L-asparaginase (L-asparaginase)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Lymphoma,, Non-Hodgkin Lymphoma, | Phase 2 | Status: UNKNOWN